On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

She blamed irritable bowel syndrome, constipation and even a tight bra. Looking back, she had some classic symptoms of colon ...

In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative ...

See "Use of Non-GAAP Financial Information". U.S. revenues increased 9% to $8.6 billion, primarily driven by higher demand for the Growth Portfolio and Eliquis, partially offset by the impact of ...

Adjuvant treatment with 160 mg aspirin daily for three years cuts recurrence rates in patients with colorectal cancer.